key: cord-1020656-0dywvavv authors: Patell, Rushad; Midha, Shonali; Kimani, Stephen; Martin, Richard; Neparidze, Natalia; Jaglal, Michael; Freed, Jason; Key, Nigel S. title: Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States date: 2020-08-22 journal: Thromb Haemost DOI: 10.1055/s-0040-1715837 sha: b51ae95e7f768d6af4735c3d20a3fc313d590b42 doc_id: 1020656 cord_uid: 0dywvavv nan The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China in December 2019 has led to an ongoing global pandemic with more than 8.5 million cases and 460,000 deaths worldwide. 1 Early reports from Wuhan, China, where the pandemic is believed to have originated, highlighted abnormal coagulation studies in patients, including elevated levels of D-dimer and fibrinogen, prolonged prothrombin time (PT), and mild thrombocytopenia. [2] [3] [4] Severe coronavirus disease-2019 (COVID-19) is associated with pulmonary microvascular thrombosis, and arterial and venous thromboembolism that has been termed COVID-associated coagulopathy (CAC). 5, 6 The pathophysiology of CAC is incompletely understood, but includes upregulation of proinflammatory cytokines that promote immunothrombosis and endothelial dysfunction leading to widespread micro-and macrovascular thrombosis. [7] [8] [9] [10] These thromboembolic events are particularly prevalent in critically ill patients (35-45%), even when compared with other critically ill patients with non-COVID-19 diagnoses (5-15%). 11 Although initial reports from China included patients who were not on thromboprophylaxis, the use of heparin thromboprophylaxis was shown to decrease mortality, especially in subsets of patients with higher D-dimer levels. 12, 13 Furthermore, studies from Europe have demonstrated high venous thromboembolism (VTE) rates despite the use of pharmacologic thromboprophylaxis. 5 Given the concern for the heightened thrombotic risk and the contribution of the ensuing hypercoagulable state to the considerable morbidity and mortality of severe COVID-19, the role of anticoagulation beyond standard thromboprophylaxis for hospitalized medical patients has been raised. Currently, several drugs targeting the thromboinflammatory pathway in COVID-19 patients are under investigation, including parenteral and oral antithrombotics, antiplatelet, and fibrinolytic agents. 14 Notably, several clinical trials are currently underway to examine the role of higher than standard dose thromboprophylaxis and even therapeutic intensity anticoagulation prophylaxis in patients with COVID-19 (e.g., NCT04359277, NCT04345848, and NCT04344756). However, in the absence of randomized clinical trial data, numerous professional societies have published interim consensus recommendations to guide clinicians based on expert consensus and observational data (►Table 1). [15] [16] [17] [18] [19] [20] These documents universally recommend standard prophylactic doses of low molecular weight heparin (LMWH) or subcutaneous unfractionated heparin (UFH) for all hospitalized patients with COVID-19. In addition, monitoring of coagulation parameters, including platelet count, PT, D-dimer, and fibrinogen, are encouraged. The American Society of Hematology guidelines published in May 2020 specifies that therapeutic anticoagulation is not required unless documented indications such as VTE or atrial fibrillation are present. 17 A notable specified exception is presumed VTE, such as acute respiratory decompensation in intubated patients with clinical and laboratory findings that are suggestive of VTE, when radiographic confirmation is not feasible. Epidemiologic data are currently lacking for postdischarge rates of VTE in COVID-19 patients, although factors including the hypercoaguable state of COVID-19, comorbidities, advanced age, and prolonged hospitalization may put these patients at higher risk. 21 Of note, three of the existing guidelines recommend postdischarge thromboprophylaxis (►Table 1). 16, 17, 20 Until more evidence-based guidelines for thromboprophylaxis are available, individual medical institutions have created their own institutional algorithms, presumably based on local individual expertise and consensus, as well as interim professional society and governmental recommendations. 21, 22 To assess the alignment of these institutional recommendations with published guidance from national and international professional societies and health authorities, we obtained local written algorithms from 15 large U.S. institutions across 11 U.S. states (►Table 2). Written treatment algorithms from these institutions were obtained by searching publicly available online algorithms or via a unique educational initiative, "Hematology and Oncology Inter-Institutional Collaborative Videoconferencing Learning," that brings together hematology and oncology fellowship trainees, faculty, and program leadership from these 15 institutions to share important updates and institutional best practices at the participating institutions. Of the 15 centers, 4 institutional algorithms (Massachusetts General Hospital, Moffit Cancer Center/University of South Florida, University of Alabama, and Vanderbilt University Medical Center) are generally consistent with evidence-based thromboprophylaxis recommendations in non-COVID-19 populations, that is, enoxaparin 40 mg subcutaneous daily (with adjustments for body mass index or renal insufficiency). Numerous laboratory and clinical parameters are recommended to risk-stratify hospitalized COVID-19 patients into intermediate or higher risk. Eight of the 15 institutions recommend using D-dimer thresholds to risk-stratify hospitalized COVID-19 patients into intermediate or higher risk, with different cutoffs recommended. For such "higher risk populations," anticoagulation strategies vary across the institutions. In 8 centers, use of an "intermediate" dose of LMWH (0.4-0.6 mg/kg two times daily) is advised for this population. An additional 4 institutions advise full-dose anticoagulation with heparins (LMWH or UFH, three institutions) or direct oral anticoagulants (DOACs) (apixaban, one institution). Although bleeding has not been raised as a major concern in hospitalized patients with COVID-19, one institution (University of Michigan) recommends using clinical prediction rules to estimate a patient's thrombotic (Wells score) and bleeding (VTE-BLEED score) risks to guide individualized decisions regarding empiric use of high-dose or therapeutic anticoagulation. Almost all algorithms agree that for situations with a high clinical suspicion for VTE without confirmatory imaging, therapeutic anticoagulation with LMWH, UFH, or DOAC is recommended. One institution (Beth Israel Deaconess Medical Center), mentions consideration of empiric fibrinolysis for salvage therapy in severe and persistent hypoxia. Extended-duration thromboprophylaxis following hospitalization, especially in critically ill patients, has been shown to be effective in reducing VTE incidence in certain high-risk populations 23, 24 ; however, data specifically for COVID-19 patients are not yet available. 25 Notably, among the 15 institutional protocols presented here, 8 include guidance on postdischarge outpatient thromboprophylaxis, recommending LMWH or DOACs for 1 to 3 months in selected higher risk subgroups. The COVID-19 pandemic has pressurized the medical community to make medical decisions and recommendations based on limited anecdotal, observational, and in some cases, a complete absence of evidence. 26 The observed increased risk for VTE has led institutional experts across the world and North America to create a variety of algorithms to guide anticoagulant use in this population, extrapolating from general experience from other subsets of patients with VTE. Here, we have collated guidelines from 15 U.S. institutions to: (1) allow comparison of similarities and differences in practice recommendations; (2) allow critical analysis of advantages and disadvantages of strategies proposed; and (3) allow other institutions both in the United States and abroad to strategize their preferred approach while awaiting more robust evidence. The wide disparity in institutional recommendations highlights the existing equipoise regarding antithrombotic management in patients with COVID-19, the lack of a true standard of care, and the need for data from robust, randomized prospective clinical trials to guide clinical practice. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China COVID-19 and its implications for thrombosis and anticoagulation COVID-19: towards understanding of pathogenesis Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Large-vessel stroke as a presenting feature of Covid-19 in the young Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels Coagulation abnormalities and thrombosis in patients with COVID-19 Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Global COVID-19 Thrombosis Collaborative GroupPharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology Endorsed by the ISTH, NATF, ESVM, and the IUA Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC stateof-the-art review COVID-19 and VTE/Anticoagulation: Frequently Asked Questions ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim Guidance Extended thromboprophylaxis in the acutely ill medical patient after hospitalization -a paradigm shift in post-discharge thromboprophylaxis Emergence of institutional antithrombotic protocols for coronavirus 2019 Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in highrisk patient groups: cancer and critically ill Impact of prolonged anticoagulation with rivaroxaban on provoked venous thromboembolism recurrence: IMPROVE-VTE APEX Investigators Extended thromboprophylaxis with betrixaban in acutely ill medical patients Drug evaluation during the Covid-19 pandemic COVID-19) Treatment Guidelines None declared.